Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries | Zendy

Ravi Goud | Zendy; Bradley Lufkin | Zendy; Jonathan Duffy | Zendy; Barbee I. Whitaker | Zendy; HuiLee Wong | Zendy; Jiemin Liao | Zendy; AnChi Lo | Zendy; Shruti Parulekar | Zendy; Paula Ehrlich Agger | Zendy; Steven A. Anderson | Zendy; Michael Wernecke | Zendy; Thomas MaCurdy | Zendy; Eric Weintraub | Zendy; Jeffrey A. Kelman | Zendy; Richard A. Forshee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries

Author(s) -

Ravi Goud,

Bradley Lufkin,

Jonathan Duffy,

Barbee I. Whitaker,

HuiLee Wong,

Jiemin Liao,

AnChi Lo,

Shruti Parulekar,

Paula Ehrlich Agger,

Steven A. Anderson,

Michael Wernecke,

Thomas MaCurdy,

Eric Weintraub,

Jeffrey A. Kelman,

Richard A. Forshee

Publication year - 2021

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2021.6227

Subject(s) - medicine , guillain barre syndrome , vaccination , pediatrics , cohort , medical record , immunology , surgery

Guillain-Barré syndrome can be reported after vaccination. This study assesses the risk of Guillain-Barré syndrome after administration of recombinant zoster vaccine (RZV or Shingrix), which is administered in 2 doses 2 to 6 months apart.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore